Tokyo, Japan

Ikuo Kajishiro

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nihon Medi-Physics Company, Limited. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ikuo Kajishiro: Innovator in Radiopharmaceutical Production

Introduction

Ikuo Kajishiro is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of radiopharmaceuticals, particularly in the production methods of radioactive isotopes. His work is essential for advancements in medical imaging and treatment.

Latest Patents

Kajishiro holds a patent for a production method of 226Ra target, a production method of 225Ac, and an electrodeposition solution for producing 226Ra target. This patent outlines a method that includes an electrodeposition step, where a 226Ra-containing substance is electrodeposited on a substrate using a solution that contains Ra ions and a pH buffer. This innovation is crucial for enhancing the efficiency and effectiveness of radiopharmaceutical production.

Career Highlights

Ikuo Kajishiro is associated with Nihon Medi-Physics Company, Limited, where he applies his expertise in radiopharmaceuticals. His work has contributed to the development of new techniques that improve the production of essential medical isotopes.

Collaborations

Kajishiro has collaborated with notable colleagues such as Shinya Yano and Jun Ichinose. These partnerships have fostered innovation and have been instrumental in advancing research in the field of radiopharmaceuticals.

Conclusion

Ikuo Kajishiro's contributions to the field of radiopharmaceuticals through his innovative patent and collaborations highlight his importance as an inventor. His work continues to impact medical science positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…